Cypress Capital Management (Wyoming)’s Juno Therapeutics, Inc. JUNO Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,075	Closed	–	–	267
2016 Q1	$0	Sell	3,075 -200	-6%	-$6.97K	﹤0.01%	246
2015 Q4	$144K	Hold	3,275	–	–	0.18%	76
2015 Q3	$133K	Sell	3,275 -900	-22%	-$39.5K	0.17%	75
2015 Q2	$223K	Buy	4,175 +400	+11%	+$21.2K	0.25%	66
2015 Q1	$229K	Buy	3,775 +3,175	+529%	+$154K	0.28%	64
2014 Q4	$31.3K	Buy	+600	New	+$26.9K	0.04%	129

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RCM

Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s JUNO Position: Q2 2016 in Review

Cypress Capital Management (Wyoming) sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2016, closing a stake of 3,075 shares.

Cypress Capital Management (Wyoming) first reported a position in JUNO in Q4 2014 and held it in 6 quarters. The position peaked at $229K in Q1 2015. 170 funds tracked by Wall St. Rank hold JUNO as of Q2 2016.

Cypress Capital Management (Wyoming) reported no remaining Juno Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Cypress Capital Management (Wyoming) sold 3,075 Juno Therapeutics, Inc. shares in Q2 2016.
Cypress Capital Management (Wyoming) first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
Cypress Capital Management (Wyoming)'s Juno Therapeutics, Inc. position peaked at $229K in Q1 2015.
170 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2016.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q2 2016, filed 28 Jul 2016.